Cefiderocol sulfate tosylate is under clinical development by Shionogi and currently in Phase III for Resistant Pseudomonas aeruginosa Infections. According to GlobalData, Phase III drugs for Resistant Pseudomonas aeruginosa Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cefiderocol sulfate tosylate LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cefiderocol sulfate tosylate overview

Cefiderocol sulfate tosylate (Fetroja, Fetcroja) belongs to cephalosporins, acts as antibacterial agent. It is formulated as powder for concentrate for solution for intravenous route of administration. Fetroja is indicated in patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and indicated for the treatment of infections due to aerobic Gram-negative organisms (complicated urinary tract infections including pyelonephritis, complicated intra-abdominal infections, hospital-acquired pneumonia including ventilator associated pneumonia) in adults (18 years or older) with limited treatment options.

Cefiderocol sulfate tosylate (S-649266, GSK-2696266, S-649266D, GSK-2696266D) is under development for the treatment of multidrug resistant pseudomonas aeruginosa (MDRP), multidrug resistant Acinetobacter baumannii (MDRA), carbapenem resistant Enterobacteriaceae (CRE) such as carbapenem resistant Klebsiella pneumoniae, hospital acquired pneumonia (HAP), ventilator associated pneumonia (VAP), healthcare-associated pneumonia (HCAP), bloodstream infections or sepsis caused by carbapenem-resistant gram-negative pathogens. It is administered intravenously as powder for solution. S-649266 is a cephalosporin and targets penicillin-binding protein.

Shionogi overview

Shionogi focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.

For a complete picture of Cefiderocol sulfate tosylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.